Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00850603 · ClinicalTrials.gov registry record · Phase 4
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®
A Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 170
- Enrollment target
NCT00850603 is a Phase 4 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 170 participants.
The verdict
NCT00850603, a Phase 4 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 170 participants
- Enrollment target
Study Summary
The objective of this trial is to study the administration of the Menomune vaccine given intradermally and low-dose subcutaneously versus standard subcutaneously. This study will describe the immunogenicity of Menomune® - A/C/Y/W-135 administered subcutaneously (standard dose) versus intradermally over a dose range (1/10th, 2/10th, and 3/10th of standard dose) and a low dose (2/10th of standard dose) subcutaneously. The secondary objective is to describe the safety of the subcutaneous (SC) and intradermal (ID) routes at different dosages
Interventions
- BIOLOGICAL Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2002-10 |
| Est. Completion | 2004-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00850603
The ClinicalTrials.gov registry entry for NCT00850603 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined is the first listed.
NCT00850603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00850603 about?
NCT00850603 is a clinical study titled "Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®". The objective of this trial is to study the administration of the Menomune vaccine given intradermally and low-dose subcutaneously versus standard subcutaneously. This study will describe the immunogenicity of Menomune® - A/C/Y/W-135 administered subcutaneously (standard dose) versus intradermally o...
What is the current status of trial NCT00850603?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 170 participants. The study started on 2002-10. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00850603?
The interventions under investigation include: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined (BIOLOGICAL).
Who is sponsoring clinical trial NCT00850603?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.